Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Outstanding
Ratios

Silence Therapeutics (SLN) Non-Current Receivables: 2019-2022

  • Silence Therapeutics' Non-Current Receivables rose 50.36% to -$3.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was -$3.0 million, marking a year-over-year increase of 50.36%. This contributed to the annual value of $5,107 for FY2019, which is N/A change from last year.
  • Silence Therapeutics' Non-Current Receivables amounted to -$3.0 million in Q1 2022, which was up 50.36% from -$6.1 million recorded in Q1 2021.
  • Over the past 5 years, Silence Therapeutics' Non-Current Receivables peaked at $40.9 million during Q2 2020, and registered a low of -$6.1 million during Q1 2021.
  • Its 3-year average for Non-Current Receivables is $10.6 million, with a median of -$3.0 million in 2022.
  • Data for Silence Therapeutics' Non-Current Receivables shows a peak YoY spiked of 50.36% (in 2022) over the last 5 years.
  • Over the past 4 years, Silence Therapeutics' Non-Current Receivables (Quarterly) stood at $5,143 in 2019, then reached $40.9 million in 2020, then reached -$6.1 million in 2021, then spiked by 50.36% to -$3.0 million in 2022.
  • Its last three reported values are -$3.0 million in Q1 2022, -$6.1 million for Q1 2021, and $40.9 million during Q2 2020.